S&P 500   4,315.53 (+0.43%)
DOW   34,223.67 (+0.92%)
QQQ   334.25 (+0.36%)
AAPL   173.38 (+0.11%)
MSFT   293.65 (+0.06%)
META   180.61 (-0.15%)
GOOGL   122.12 (+0.03%)
AMZN   146.03 (+1.99%)
TSLA   930.41 (+0.26%)
NVDA   190.49 (+0.09%)
NIO   21.01 (-1.36%)
BABA   93.39 (-0.86%)
AMD   100.92 (-0.09%)
MU   64.41 (-0.45%)
T   18.67 (+1.52%)
CGC   3.88 (+1.57%)
F   16.65 (+2.02%)
GE   81.09 (+1.60%)
DIS   126.28 (+1.63%)
AMC   25.69 (+6.11%)
PYPL   102.92 (+1.39%)
PFE   50.04 (+0.58%)
NFLX   248.82 (-0.12%)
S&P 500   4,315.53 (+0.43%)
DOW   34,223.67 (+0.92%)
QQQ   334.25 (+0.36%)
AAPL   173.38 (+0.11%)
MSFT   293.65 (+0.06%)
META   180.61 (-0.15%)
GOOGL   122.12 (+0.03%)
AMZN   146.03 (+1.99%)
TSLA   930.41 (+0.26%)
NVDA   190.49 (+0.09%)
NIO   21.01 (-1.36%)
BABA   93.39 (-0.86%)
AMD   100.92 (-0.09%)
MU   64.41 (-0.45%)
T   18.67 (+1.52%)
CGC   3.88 (+1.57%)
F   16.65 (+2.02%)
GE   81.09 (+1.60%)
DIS   126.28 (+1.63%)
AMC   25.69 (+6.11%)
PYPL   102.92 (+1.39%)
PFE   50.04 (+0.58%)
NFLX   248.82 (-0.12%)
S&P 500   4,315.53 (+0.43%)
DOW   34,223.67 (+0.92%)
QQQ   334.25 (+0.36%)
AAPL   173.38 (+0.11%)
MSFT   293.65 (+0.06%)
META   180.61 (-0.15%)
GOOGL   122.12 (+0.03%)
AMZN   146.03 (+1.99%)
TSLA   930.41 (+0.26%)
NVDA   190.49 (+0.09%)
NIO   21.01 (-1.36%)
BABA   93.39 (-0.86%)
AMD   100.92 (-0.09%)
MU   64.41 (-0.45%)
T   18.67 (+1.52%)
CGC   3.88 (+1.57%)
F   16.65 (+2.02%)
GE   81.09 (+1.60%)
DIS   126.28 (+1.63%)
AMC   25.69 (+6.11%)
PYPL   102.92 (+1.39%)
PFE   50.04 (+0.58%)
NFLX   248.82 (-0.12%)
S&P 500   4,315.53 (+0.43%)
DOW   34,223.67 (+0.92%)
QQQ   334.25 (+0.36%)
AAPL   173.38 (+0.11%)
MSFT   293.65 (+0.06%)
META   180.61 (-0.15%)
GOOGL   122.12 (+0.03%)
AMZN   146.03 (+1.99%)
TSLA   930.41 (+0.26%)
NVDA   190.49 (+0.09%)
NIO   21.01 (-1.36%)
BABA   93.39 (-0.86%)
AMD   100.92 (-0.09%)
MU   64.41 (-0.45%)
T   18.67 (+1.52%)
CGC   3.88 (+1.57%)
F   16.65 (+2.02%)
GE   81.09 (+1.60%)
DIS   126.28 (+1.63%)
AMC   25.69 (+6.11%)
PYPL   102.92 (+1.39%)
PFE   50.04 (+0.58%)
NFLX   248.82 (-0.12%)
NASDAQ:JNCE

Jounce Therapeutics - JNCE Stock Forecast, Price & News

$4.75
-0.12 (-2.46%)
(As of 08/16/2022 02:22 PM ET)
Add
Compare
Today's Range
$4.70
$4.86
50-Day Range
$2.80
$4.92
52-Week Range
$2.76
$9.81
Volume
2,366 shs
Average Volume
266,940 shs
Market Capitalization
$245.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.40

Jounce Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
159.4% Upside
$12.40 Price Target
Short Interest
Bearish
7.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
0.59mentions of Jounce Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.30) to ($2.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

546th out of 1,124 stocks

Biological Products, Except Diagnostic Industry

79th out of 176 stocks

JNCE stock logo

About Jounce Therapeutics (NASDAQ:JNCE) Stock

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.

Jounce Therapeutics Trading Up 3.4 %

Shares of NASDAQ:JNCE traded up $0.16 during mid-day trading on Monday, reaching $4.87. The stock had a trading volume of 97,531 shares, compared to its average volume of 344,412. The company has a market cap of $251.75 million, a P/E ratio of -1.91 and a beta of 1.17. Jounce Therapeutics has a 1 year low of $2.76 and a 1 year high of $9.81. The business's 50 day moving average price is $3.42 and its 200 day moving average price is $5.32.

Wall Street Analyst Weigh In

JNCE has been the subject of a number of recent research reports. StockNews.com upgraded Jounce Therapeutics from a "sell" rating to a "hold" rating in a research note on Friday, August 5th. Piper Sandler cut their price objective on Jounce Therapeutics from $17.00 to $9.00 and set an "overweight" rating for the company in a report on Monday, May 23rd. Raymond James raised Jounce Therapeutics from an "outperform" rating to a "strong-buy" rating and boosted their price target for the company from $15.00 to $20.00 in a report on Friday, May 6th. HC Wainwright cut their price target on Jounce Therapeutics from $15.00 to $11.00 and set a "buy" rating for the company in a report on Friday, August 5th. Finally, Robert W. Baird cut their price target on Jounce Therapeutics to $5.00 in a report on Tuesday, August 9th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $12.40.

Receive JNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jounce Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

JNCE Stock News Headlines

Jounce Therapeutics (NASDAQ:JNCE) Price Target Cut to $5.00
Jounce Therapeutics Inc Stock Quote JNCE
4 Analysts Have This to Say About Jounce Therapeutics
Jounce Therapeutics Q1 2022 Earnings Preview
Jounce Therapeutics Q4 2021 Earnings Preview
Recap: Jounce Therapeutics Q4 Earnings
See More Headlines
Receive JNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jounce Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

JNCE Company Calendar

Last Earnings
11/04/2021
Today
8/16/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:JNCE
Fax
N/A
Employees
137
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.40
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+161.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-90,870,000.00
Pretax Margin
-400.86%

Debt

Sales & Book Value

Annual Sales
$26.91 million
Book Value
$4.37 per share

Miscellaneous

Free Float
48,117,000
Market Cap
$245.53 million
Optionable
Optionable
Beta
1.17

Key Executives

  • Dr. Richard Murray Ph.D. (Age 63)
    Pres, CEO & Director
    Comp: $887.4k
  • Mr. Hugh M. Cole (Age 57)
    Chief Bus. Officer & Head of Corp. Devel.
    Comp: $607.44k
  • Dr. Elizabeth G. Trehu M.D. (Age 62)
    Chief Medical Officer
    Comp: $639.6k
  • Dr. James Patrick Allison Ph.D.
    Founder
  • Dr. Thomas F. Gajewski M.D.
    Ph.D., Founder
  • Dr. Robert D. Schreiber Ph.D.
    Founder
  • Dr. Drew Mark Pardoll M.D.
    Ph.D., Founder
  • Dr. Padmanee Sharma M.D.
    Ph.D., Founder
  • Dr. Louis M. Weiner M.D. (Age 70)
    Founder
  • Ms. Kimberlee Cobleigh Drapkin CPA (Age 54)
    CPA, CFO & Treasurer













JNCE Stock - Frequently Asked Questions

Should I buy or sell Jounce Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last twelve months. There are currently 1 hold rating, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" JNCE shares.
View JNCE analyst ratings
or view top-rated stocks.

What is Jounce Therapeutics' stock price forecast for 2022?

7 Wall Street research analysts have issued 12 month price targets for Jounce Therapeutics' shares. Their JNCE share price forecasts range from $5.00 to $20.00. On average, they expect the company's stock price to reach $12.40 in the next twelve months. This suggests a possible upside of 154.6% from the stock's current price.
View analysts price targets for JNCE
or view top-rated stocks among Wall Street analysts.

How have JNCE shares performed in 2022?

Jounce Therapeutics' stock was trading at $8.35 at the start of the year. Since then, JNCE shares have decreased by 41.7% and is now trading at $4.87.
View the best growth stocks for 2022 here
.

When is Jounce Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our JNCE earnings forecast
.

How were Jounce Therapeutics' earnings last quarter?

Jounce Therapeutics, Inc. (NASDAQ:JNCE) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.44) by $0.15. During the same quarter in the previous year, the business earned ($0.73) EPS.

What is Richard Murray Ph.D's approval rating as Jounce Therapeutics' CEO?

45 employees have rated Jounce Therapeutics Chief Executive Officer Richard Murray Ph.D on Glassdoor.com. Richard Murray Ph.D has an approval rating of 97% among the company's employees. This puts Richard Murray Ph.D in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Jounce Therapeutics own?
When did Jounce Therapeutics IPO?

(JNCE) raised $76 million in an initial public offering (IPO) on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

What is Jounce Therapeutics' stock symbol?

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

Who are Jounce Therapeutics' major shareholders?

Jounce Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Cowen AND Company LLC (5.50%), Citadel Advisors LLC (3.28%), Assenagon Asset Management S.A. (2.65%), FMR LLC (2.45%), State Street Corp (1.27%) and Congress Asset Management Co. MA (1.05%). Insiders that own company stock include Barbara Gayle Duncan, Elizabeth Trehu, Hugh M Cole, John Duncan Higgons, Kimberlee C Drapkin, Richard /Ca/ Murray, Rock Ventures Ii LP Third and Rock Ventures Iii LP Third.
View institutional ownership trends
.

How do I buy shares of Jounce Therapeutics?

Shares of JNCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Jounce Therapeutics' stock price today?

One share of JNCE stock can currently be purchased for approximately $4.87.

How much money does Jounce Therapeutics make?

Jounce Therapeutics (NASDAQ:JNCE) has a market capitalization of $251.73 million and generates $26.91 million in revenue each year. The company earns $-90,870,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis.

How many employees does Jounce Therapeutics have?

The company employs 137 workers across the globe.

How can I contact Jounce Therapeutics?

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for the company is www.jouncetx.com. The company can be reached via phone at (857) 259-3840 or via email at mdeon@jouncetx.com.

This page (NASDAQ:JNCE) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.